Literature DB >> 30714153

Sonic hedgehog pathway activation regulates cervical cancer stem cell characteristics during epithelial to mesenchymal transition.

Anuka Sharma1, Renaissa De1, Shifa Javed2, Radhika Srinivasan2, Arnab Pal3, Shalmoli Bhattacharyya1.   

Abstract

Resistance to therapy and metastasis remains one of the leading causes of mortality due to cervical cancer despite advances in detection and treatment. The mechanism of epithelial to mesenchymal transition (EMT) provides conceptual explanation to the invasiveness and metastatic spread of cancer but it has not been fully understood in cervical cancer. This study aims to investigate the mechanism by which silencing of E-cadherin gene regulates EMT leading to proliferation, invasion, and chemoresistance of cervical cancer cells through the Hedgehog (Hh) signaling pathway. We developed an in vitro EMT model by the knockdown of E-cadherin expression in cervical cancer cell lines. To understand the role of developmental pathway like Hh in the progression of cervical cancer, we investigated the expression of Hh pathway mediators by array in E-cadherin low cervical cancer cells and observed upregulation of Hh pathway. This was further validated on low passage patient-derived cell lines and cervical carcinoma tissue sections from cervical cancer patients. Further, we evaluated the role of two inhibitors (cyclopamine and GANT58) of the Hh pathway on invasiveness and apoptosis in E-cadherin low cervical cancer cells. In conclusion, we observed that inhibition of Hh pathway with GANT58 along with current therapeutic procedures could be more effective in targeting drug-resistant EMT cells and bulk tumor cells in cervical cancer.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  EMT; GANT58; Hedgehog pathway; cancer stem cells; cervical cancer; drug resistance

Year:  2019        PMID: 30714153     DOI: 10.1002/jcp.28231

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

Review 1.  Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities.

Authors:  Zhao Huang; Zhe Zhang; Chengwei Zhou; Lin Liu; Canhua Huang
Journal:  MedComm (2020)       Date:  2022-05-18

2.  Moderate Alcohol Consumption Targets S100β+ Vascular Stem Cells and Attenuates Injury-Induced Neointimal Hyperplasia.

Authors:  Weimin Liu; Suzie Harman; Mariana DiLuca; Denise Burtenshaw; Eoin Corcoran; Paul A Cahill; Eileen M Redmond
Journal:  Alcohol Clin Exp Res       Date:  2020-08-02       Impact factor: 3.455

3.  Silencing of KCNA1 suppresses the cervical cancer development via mitochondria damage.

Authors:  Li Liu; Yumei Chen; Qingyuan Zhang; Changzhong Li
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

4.  Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model.

Authors:  Natalia Garcia; Mara Ulin; Mohamed Ali; Ayman Al-Hendy; Katia Candido Carvalho; Qiwei Yang
Journal:  Reprod Sci       Date:  2021-10-12       Impact factor: 3.060

Review 5.  Regulation of the Cancer Stem Phenotype by Long Non-Coding RNAs.

Authors:  Jose Adan Gutierrez-Cruz; Vilma Maldonado; Jorge Melendez-Zajgla
Journal:  Cells       Date:  2022-07-30       Impact factor: 7.666

6.  Resveratrol Induces Apoptosis, Suppresses Migration, and Invasion of Cervical Cancer Cells by Inhibiting the Hedgehog Signaling Pathway.

Authors:  Jie Jiang; Zhenghua Liu; Xiuping Zhou; Fenglan Peng; Zhihui Wang; Feng Li; Ming Li
Journal:  Biomed Res Int       Date:  2022-10-07       Impact factor: 3.246

7.  The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth.

Authors:  Xueli Hu; Jie Ding; Ge Wang; Xianming Zhang
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

8.  The Role of Hedgehog Pathway in Female Cancers.

Authors:  Natalia Garcia; Mara Ulin; Ayman Al-Hendy; Qiwei Yang
Journal:  J Cancer Sci Clin Ther       Date:  2020-10-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.